Qlife - Soft-launch of their first CRP biomarker test under the Egoo Health brand

Qlife recently soft-launched their first CRP biomarker test under the Egoo Health brand.

The vision the company has for this innovation is that it can be used by healthcare professionals to provide more personalized care to their patients. Furthermore, the portability and usability of the test allows for patients to take control over their health from their home as well.

Qlife met with Dr. Olivia Lesslar, a medical doctor that focuses on functional medicine, who provided some insights into how at-home testing can be used to bridge the gap between patients and health professionals. Olivia discussed how at-home biomarker testing is already being utilized by many individuals in the case of glucose monitoring.

However, Egoo is opening the door to even more possibilities with new biomarkers such as CRP that have the potential to inform the effectiveness of interventions, provide a more individualized approach to health programs, and more. She believes that Egoo has the capability to empower people by giving them the tools to take action on their own health, but also states that anyone considering monitoring their biomarkers at home “should have some oversight by a doctor as well, or someone who's a health practitioner, who understands your journey and your goals”. Dr. Olivia views her patients coming in having done their own research and their own testing as an advantage to her work, as long as they are doing it safely. The health and safety of patients is every health practitioners main concern, Dr. Olivia being no exception, as she puts in her own words: “as a doctor, one of my main goals with patients is to keep them safe. But absolutely, when patients walk through the door, having had done their own research, having their own information, doing their own testing at home, and they bring it to the table, it does make my job easier, especially if they walk into a consulting room with an open mind”. When patients do their own work to understand their health, the conversation between health professionals and patients is no longer one-sided, it becomes a collaboration between two individuals working towards the same goal. Both Qlife and Dr. Olivia agree that the future of healthcare is helping people to understand that the future of their health is in their hands.

Meet Dr. Olivia Lesslar here: https://youtu.be/KyKcTalJ7Is

Disclaimer:

Qlife has recently soft-launched their first CRP biomarker test with no medical claims for Health Practitioners and home market.

Qlife Holding AB is a med-tech group that strives to revolutionize the market for clinical biomarker and virus tests. By enabling tests at home as a complement to tests in healthcare, access to important health information is facilitated, which can contribute to better treatment and potentially prevent diseases.

Qlife Holding was formed in October 2019 and received the certification ISO 13485:2016 the same year, which means that Qlife meets all requirements for the manufacture and sale of in-vitro diagnostic analyzers and reagents. The first capsules in the company's product, Egoo.Health Platform, were CE marked for professional use in early 2020. The company has patent protection for key parts of its technology.

Qlife Holding AB is listed on Nasdaq First North Stockholm with ticker QLIFE.

Disclaimer:

HC Andersen Capital receives payment from Qlife for a Digital IR/Corporate Visibility subscription agreement. /ANALYST Claus Thestrup 08:40 AM 03-04-2023